CiVi Biopharma
CiVi Biopharma is a privately-held, clinical-stage biotechnology company founded in 2016 in Chevy Chase, Maryland, developing novel cardiovascular therapeutics. The company has raised approximately $89 million across two funding rounds led by Boxer Capital with strategic and crossover healthcare investors.
- Company typePrivate
- Founded2016
- HeadquartersChevy Chase, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CiVi Biopharma does
CiVi Biopharma is a privately-held, clinical-stage research and development biotechnology company founded in 2016 and headquartered in Chevy Chase, Maryland. Per the firmographic record, the company's stated mission is to create novel cardiovascular therapeutics, placing it within the cardiovascular drug development segment of the biopharmaceutical industry. The company operates with a small team (11-50 employees) consistent with a venture-backed early-clinical-stage operation, and is led by CEO Shalom Jacobovitz, Chief Scientific Officer Henrik Orum, and co-founder Jess Thiersen.
The company has raised approximately $89 million across two disclosed funding rounds: a $40 million Series 2 in January 2017 led by Boxer Capital, and a $49 million financing in May 2018 that broadened the syndicate to include RA Capital Management, Roche Venture Fund, and Tang Capital Management. The composition of this investor base — a mix of dedicated healthcare specialists, a crossover fund, and a strategic pharma venture arm — is consistent with a clinical-stage biotech positioning for either a near-term value-inflection event or a future strategic transaction. The presence of Roche Venture Fund in particular introduces potential optionality for partnership, licensing, or acquisition. However, no pipeline candidates, mechanism-of-action details, clinical trial readouts, or partnership arrangements are disclosed in the available source material.
Public information is currently materially constrained: the company's website (civibio.com) is under maintenance and does not disclose products, technology, customers, pricing, geographies served, awards, patents, or detailed management biographies. The most recent observable signal is the 2018 capital raise; no subsequent funding rounds, leadership changes, product launches, or regulatory actions are documented in the input. As a result, the company's current operating status, pipeline progression, and strategic trajectory beyond 2018 cannot be independently verified from the supplied data, and should be treated as a significant information gap for any investment decision.
CiVi Biopharma firmographics
Firmographics- Name
- CiVi Biopharma
- Legal name
- CiVi Biopharma
- Website
- https://civibio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CiVi Biopharma is a privately-held, clinical-stage biotechnology company founded in 2016 in Chevy Chase, Maryland, developing novel cardiovascular therapeutics. The company has raised approximately $89 million across two funding rounds led by Boxer Capital with strategic and crossover healthcare investors.
- Ownership category
- akta.pro rank
CiVi Biopharma industry classification
Industry- Product category
- Cardiovascular Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
Keywords
Where CiVi Biopharma is headquartered
LocationHeadquarters
- HQ city
- Chevy Chase
- HQ country
- United States
- HQ region
- North America
Markets served
CiVi Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
CiVi Biopharma product offering
Product offeringCore offering
CiVi Biopharma is a clinical-stage research and development biotechnology company developing novel therapeutics for cardiovascular diseases. The company concentrates its scientific efforts on advancing drug candidates through preclinical and clinical development to address unmet medical needs in cardiovascular medicine.
Differentiator
Problem solved
Functional benefit
Companies that use CiVi Biopharma
Customer profileIdeal customer profiles1 record
CiVi Biopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CiVi Biopharma partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
CiVi Biopharma competitors and assessment
Company assessmentDirect peers
- Anthos Therapeutics: Clinical-stage cardiovascular biotech developing abelacimab for thrombotic disease. Comparable as a focused clinical-stage cardiovascular company with a single lead asset in development.
- Esperion Therapeutics: Clinical-stage to commercial cardiovascular biotech focused on lipid-lowering therapies. Highly comparable to CiVi as a single-indication cardiovascular company pursuing novel mechanisms against well-established incumbents.
- Madrigal Pharmaceuticals: Cardiometabolic biotech that developed resmetirone for MASH/NASH with cardiovascular outcomes. Comparable as a focused cardiometabolic therapeutics company that built a clinically validated asset from a small private base.
- Tenaya Therapeutics: Clinical-stage biotech developing genetic and regenerative cardiovascular therapies, including treatments for heart failure and cardiomyopathies. Comparable in being a small, clinical-stage cardiovascular-focused biotech with novel therapeutic approaches.
- Verve Therapeutics: Clinical-stage cardiovascular biotech developing in vivo gene editing therapies targeting PCSK9 and other lipid/cardiovascular targets. Comparable as a focused, well-funded cardiovascular therapeutics company pursuing novel mechanisms with strong syndicate support.
- Lexicon Pharmaceuticals: Clinical-stage cardiovascular and cardiometabolic biotech with a pipeline addressing heart failure and metabolic disease. Comparable as a smaller-cap cardiovascular-focused clinical-stage peer.
- Keros Therapeutics: Clinical-stage biotech with a cardiovascular and hematology pipeline, focused on TGF-beta family therapeutics. Comparable as a small-cap clinical-stage company with cardiovascular programs and a similar capital base.
- CinCor Pharma: Clinical-stage cardiovascular biotech developing aldosterone synthase inhibitors for resistant hypertension and cardiovascular disease before its acquisition by AstraZeneca. Comparable as a clinical-stage cardiovascular biotech with a single-asset focus and similar corporate trajectory.
- Resverlogix: Late-stage clinical biotech developing apabetalone for cardiovascular disease and other indications. Comparable as a small cardiovascular-focused clinical-stage biotech working on novel mechanisms in atherosclerotic disease.
Emerging players
- Arcturus Therapeutics: Clinical-stage biotech with cardiovascular and rare disease programs alongside its broader RNA therapeutics pipeline. Comparable as a clinical-stage company with cardiovascular programs and novel modality approaches.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key highlights5 records
Customer concentration
CiVi Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
CiVi Biopharma leadership team
Management profileNumber of profiles
Profiles3 records
CiVi Biopharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CiVi Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CiVi Biopharma
What does CiVi Biopharma do?
CiVi Biopharma is a clinical-stage research and development biotechnology company developing novel therapeutics for cardiovascular diseases. The company concentrates its scientific efforts on advancing drug candidates through preclinical and clinical development to address unmet medical needs in cardiovascular medicine.
Is CiVi Biopharma a public or private company?
CiVi Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was CiVi Biopharma founded?
CiVi Biopharma was founded in 2016. It employs 11 to 50 people.
Where is CiVi Biopharma based?
CiVi Biopharma is headquartered in Chevy Chase, United States, in the North America region.
Who are CiVi Biopharma's main competitors?
Direct peers on record are Anthos Therapeutics, Esperion Therapeutics, Madrigal Pharmaceuticals, Tenaya Therapeutics, Verve Therapeutics, Lexicon Pharmaceuticals, Keros Therapeutics, CinCor Pharma and Resverlogix. Arcturus Therapeutics is listed as an emerging player.
Does CiVi Biopharma have an API?
No public API is recorded for CiVi Biopharma.
What industry is CiVi Biopharma in?
CiVi Biopharma's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.